Vol. 25/No. 12

home / publications / oncology-live / vol-25-no-12
Erin Crum, MPH, senior director, quality strategy and innovation, The US Oncology Network

McKesson's Patient-Reported Outcomes Measure Will Track Improvements in Health-Related Social Needs

Erin Crum, MPH;Lydia Mills, MSW, LCSW, LICSW
October 16th 2024
ArticlePartner Perspective

The use of patient-reported outcome measures—the gold standard in quality measurement—is crucial to building a patient-centered, value-based care system.

Aditya Bardia, MD, MPH, FASCO, of UCLA

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

Kyle Doherty
October 15th 2024
ArticlePathways

Ian Krop, MD, PhD, and Aditya Bardia, MD, MPH, FASCO, detail how TROP2-directed ADCs have generated excitement in breast cancer and other solid tumors.

Mark G. Kris, MD, thoracic medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center

Chemoimmunotherapy Is at the Forefront of the Perioperative NSCLC Paradigm

Megan Hollasch
October 14th 2024
ArticleCover Story

Combination therapies with neoadjuvant ICIs and chemotherapy followed by an adjuvant ICI are here to stay in resectable non–small cell lung cancer.

Kristen K. Ciombor, MD, MSCI

Treatment Personalization Is Poised to Define New Era of mCRC Therapy

Kyle Doherty
October 11th 2024
ArticlePeer Exchange

A panel of clinicians in the CRC field discussed findings from pivotal clinical trials that were primarily shared during the 2024 ASCO Annual Meeting.

Maurie Markman, MD

Molecularly Targeted Therapeutics Are Precisely Aimed

Maurie Markman, MD
October 10th 2024
ArticleFrom the Editor

Maurie Markman, MD, details how the precision-medicine paradigm is a highly rational platform for antineoplastic drug development.

Jeff Patton, MD

Medicare Drug Price Negotiations Will Have Domino Effect for Community Oncology Practices

Megan Hollasch
September 24th 2024
ArticleOncology Business Management

Medicare drug price negotiations may impact community oncology practices, leading to potential changes in drug access, reimbursement, and patient care strategies.